Dr. Alessandro Riva

Alessandro Riva joined Transgene in 2022 as Chairman of the Board of Directors and became Chief Executive Officer in 2023. He brings nearly 30 years’ experience in the Life Sciences industry, in pharmaceutical and biotech companies.

He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and CEO of Ichnos Sciences. Alessandro Riva was also Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma and led its integration and growth. He also managed the US and EU approvals of Yescarta, the first approved CAR-T cell therapy for adult patients with diffuse large B cell lymphoma. Prior to Gilead, Alessandro Riva was EVP, Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals. Alessandro Riva currently serves on the Boards of BeOne and Century Therapeutics.

He received his bachelor’s degree in medicine and surgery from the University of Milan and a certificate board in oncology and hematology from the same institution.